Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009

Similar documents
Wireless Capsule Endoscopy

Corporate Medical Policy

Urea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013

MEDICAL POLICY EFFECTIVE DATE: 05/19/11 REVISED DATE: 05/24/12, 05/23/13 ARCHIVED DATE: 05/22/14 EDITED DATE: 05/28/15, 05/25/16, 05/18/17, 05/17/18

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008

Electric Current Therapy (Iontophoresis) E/I ELECTRIC CURRENT THERAPY (IONTOPHORESIS) HS-237. Policy Number: HS-237. Original Effective Date: 1/9/2014

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA

Clinical Policy Title: Noninvasive testing for H. pylori

Clinical Policy Title: Noninvasive testing for H. pylori

Clinical Policy: Helicobacter Pylori Serology Testing Reference Number: CP.MP.153

Clinical Policy Title: Noninvasive testing for H. pylori

Clinical Policy Title: Breath Testing for H. Pylori

Clinical Policy Title: Noninvasive testing for H. pylori

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

Peptic Ulcer Disease Update

Trigger Point Injections TRIGGER POINT INJECTIONS HS-184. Policy Number: HS-184. Original Effective Date: 7/1/2010

Helicobacter and gastritis

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

Functional Dyspepsia. Norbert Welkovics Heine van der Walt

PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School

Treatment of Helicobacter pylori Infection

Management of dyspepsia and of Helicobacter pylori infection

National Digestive Diseases Information Clearinghouse

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

Management of Dyspepsia

Peptic ulcer disease Disorders of the esophagus

June By: Reza Gholami

GI update. Common conditions and concerns my patients frequently asked about

QUICK QUERIES. Topical Questions, Sound Answers

Peer Support Services (Georgia)

The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus

TRANSPARENCY COMMITTEE OPINION. 13 December 2006

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

Magaji et al., Afr. J. Infect. Dis. 2(2): THE ROLE OF AN AGGRESSIVE FACTOR IN PEPTIC ULCER DISEASE (PUD)

6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

HCPCS Codes (Alphanumeric, CPT AMA) ICD-9-CM Codes Covered by Medicare Program

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?

Summary of the Home Health Prospective Payment System Final Rule FY 2014

Disclosures. Co-founder and Chief Science Officer, TechLab

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Policy Evaluation: Proton Pump Inhibitors (PPIs)

NCD for Fecal Occult Blood Test

Gilles Jequier. Commercial Director Organobalance, a Novozymes Company

SARCINA VENTICULARI IS A POSSIBLE CAUSATIVE MICROORGANISM OTHER THAN H.PYLORI IN GASTRIC OUTLET OBSTRUCTION PATHOGENESIS

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

The Nobel Prize in Physiology or Medicine for 2005

What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?

Epidemiology of Peptic Ulcer Disease

High use of maintenance therapy after triple therapy regimes in Ireland

Gastric And Duodenal Ulcer

KEYWORDS Dyspepsia, Acid Peptic Disease, Helicobacter Pylori, Urease, Giemsa, Peptic Ulcer, Non-Ulcer Dyspepsia.

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

EDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.

Cardiac Rehabilitation

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

Comparative study of invasive methods for diagnosis of Helicobacter pylori in humans

Peptic ulcer disease. Nomin-Erdene. D SOM-531

CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University

1. Appropriateness of Gastroscopy: Dyspepsia 1

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

Stomach Pain Evidence-Based Methods in the Diagnosis and Treatment of Dyspepsia

Outline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments

Fecal incontinence causes 196 epidemiology 8 treatment 196

Helicobacter pylori:an Emerging Pathogen

Last Revised: September 15 Last Reviewed: September EOSINOPHILIC ESOPHAGITIS (EOE)/PPI-RESPONSIVE ESOPHAGEAL EOSINOPHILIA (PPI-REE)

McHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #10 Acute GI Bleeds

A PLACEBO CONTROLLED TRIAL OF BISMUTH SALICYLATE IN HELICOBACTER PYLORI ASSOCIATED GASTRITIS

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection

Helicobacter Connections. Barry Marshall

H. pylori Antigen ELISA Kit

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment)

OPEN ACCESS TEXTBOOK OF GENERAL SURGERY

Correlation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori

UPPER GI DISEASES 11/15/2014. Lesson Objectives. GI Tract Review. NUTR 2050 Nutrition for Nursing Professionals. Mrs. Deborah A. Hutcheon, MS, RD, LD

Non-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics

Module 2 Heartburn Glossary

Gastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D

Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe

Gastroenterology Tutorial

One-third of adults experience pain or discomfort in

Peptic Ulcer (Seminar) READ ONLINE

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師


58 year old male complaining of 3-week history of increasing epigastric pain

Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis.

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

A Trip Through the GI Tract: Common GI Diseases and Complaints. Jennifer Curtis, MD

SUPPLEMENTARY INFORMATION Associated with

Setting The setting was secondary care. The economic study was carried out in Hong Kong, China.

Dyspepsia is a problem commonly seen by primary

Medical Necessity Guidelines: Upper GI Endoscopy: Certain Elective Procedures

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint

Transcription:

Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois, Inc. WellCare Health Plans of New Jersey, Inc. WellCare Health Insurance of Arizona, Inc. WellCare of Florida, Inc. WellCare of Connecticut, Inc. WellCare of Georgia, Inc. WellCare of Kentucky, Inc. WellCare of Louisiana, Inc. WellCare of New York, Inc. WellCare of South Carolina, Inc. WellCare of Texas, Inc. WellCare Prescription Insurance, Inc. Windsor Health Plan Windsor Rx Medicare Prescription Drug Plan Helicobacter Pylori Testing Policy Number: Original Effective Date: 9/17/2009 Revised Date(s): 9/24/2010; 9/1/2011; 9/6/2012; 8/1/2013; 8/7/2014; 7/11/2015 APPLICATION STATEMENT The application of the Clinical Coverage Guideline is subject to the benefit determinations set forth by the Centers for Medicare and Medicaid Services (CMS) National and Local Coverage Determinations and state-specific Medicaid mandates, if any.

DISCLAIMER The Clinical Coverage Guideline is intended to supplement certain standard WellCare benefit plans. The terms of a member s particular Benefit Plan, Evidence of Coverage, Certificate of Coverage, etc., may differ significantly from this Coverage Position. For example, a member s benefit plan may contain specific exclusions related to the topic addressed in this Clinical Coverage Guideline. When a conflict exists between the two documents, the Member s Benefit Plan always supersedes the information contained in the Clinical Coverage Guideline. Additionally, Clinical Coverage Guidelines relate exclusively to the administration of health benefit plans and are NOT recommendations for treatment, nor should they be used as treatment guidelines. The application of the Clinical Coverage Guideline is subject to the benefit determinations set forth by the Centers for Medicare and Medicaid Services (CMS) National and Local Coverage Determinations and state-specific Medicaid mandates, if any. Note: The lines of business (LOB) are subject to change without notice; consult www.wellcare.com/providers/ccgs for list of current LOBs. BACKGROUND H. pylori is a spiral-shaped, gram-negative bacterium found in the gastric mucosa or attached to the epithelial lining of the stomach. The organism weakens the protective mucous coating of the stomach and duodenum, allowing acid to get through to the sensitive lining beneath. Both the acid and the bacteria irritate the lining and cause the ulcer. H. pylori is able to survive in stomach acid because it secretes enzymes that neutralize the acid. Acute infection is commonly asymptomatic but may be associated with epigastric burning, abdominal distention or bloating, belching, nausea, flatulence, and/or halitosis. Almost all members infected with H. pylori who have had endoscopic biopsies are found to have histological gastritis. H. pylori infection can lead to ulceration of the gastric mucosa and duodenum and has been found to be strongly associated with the development of epithelial and lymphoid malignancies of the stomach. It has been classified by the International Agency for Research on Cancer as a group I carcinogen and a definite cause of gastric cancer in humans. Associations have been made between H. pylori and both dyspepsia and gastroesophageal reflux disease (GERD). Dyspepsia is clinically defined as nausea, epigastric pain or discomfort experienced on more than seven days of a four-week period. Factors that affect the management of dyspepsia include the patient s age, routine use of NSAIDs, and presence of any alarm symptoms. Alarm symptoms are identified as melena, hematemesis, persistent vomiting, anemia, acute onset of total dysphagia or involuntary weight loss greater than 5%. The procedure of choice for evaluation of dyspepsia is endoscopy, especially when alarm symptoms are present. For patients with a documented history of PUD who present with dyspepsia in the absence of reflux or alarm symptoms, management should begin with testing for H. pylori, followed by eradication therapy if results are positive. It has not been proven that eradication of H. pylori improves symptoms in patients with non-ulcer dyspepsia. 1 In February 2012, the FDA approved the first test for use in children ages 3 to 17 to detect Helicobacter pylori bacterial infections. (Hayes, 2012). The BreathTek Urea Blood Test (BreathTek UBT ) was first approved for adults in 1996. According to the product labeling, BreathTek UBT should not be used until at least 4 weeks after completing treatment to eradicate H. pylori, as earlier posttreatment assessment may give false-negative results. In addition, atimicrobials, proton pump inhibitors, and bismuth preparations are known to suppress H. pylori. Ingestion of these within 2 weeks prior to performing the BreathTek UBT may give false-negative results. 2 Hayes 3 also reports that a study published in Lancet suggests that, in a European population, a combination of four agents over 10 days can safely eradicate helicobacter pylori (H. pylori) infection. Most international treatment guidelines recommend a 7-day regimen of three drugs, which has been associated with a loss of efficacy due to an increase in antibiotic resistance. POSITION STATEMENT Applicable To: Medicaid All Markets Medicare All Markets The following methods are considered medically necessary for diagnosing Helicobacter pylori (H. pylori) infection: Endoscopic biopsy with urease testing, histology and/or culture Clinical Coverage Guideline page 2

H. pylori stool antigen (HpSA) Serology in individuals not previously treated for H. pylori infection Urea breath testing (criteria outlined below) The H. pylori urea breath test is considered medically necessary in the following circumstances: Member with uncomplicated symptoms of peptic ulcer disease for whom antibiotic therapy is planned, if H. pylori breath test is positive, and no endoscopy is planned; OR, Members who have had an upper gastrointestinal endoscopy and in whom no helicobacter testing was performed; OR, Members who have non-specific dyspeptic symptoms with a positive H. pylori serum antibody test, and no endoscopy is planned; OR, An upper gastrointestinal contrast X-ray series has been done that shows a duodenal ulcer or significant gastritis and/or duodenitis, and no endoscopy is planned; OR, There are persistent or recurrent symptoms six weeks after treatment for a documented H. pylori infection, and no endoscopy is planned; OR, Anyone with complications from peptic ulcer disease after appropriate antibiotic/h3 antagonist treatment, to establish a bacterial cure. The H. pylori breath test is considered NOT medically necessary in the following circumstances: Members who are being (V74.9) screened for H. pylori infection in the absence of documented upper gastrointestinal tract symptoms and/or pathology; OR, Members who have had an upper gastrointestinal endoscopy within the preceding six weeks and helicobacter testing was performed, or for whom an upper gastrointestinal endoscopy is planned who have not been treated for H. pylori; OR, Members who have non-specific dyspeptic symptoms with a negative H. pylori serum antibody test or a negative H. pylori stool antigen test; OR, Members who are asymptomatic after treatment of an H. pylori infection except in the situation of a history of a major complication of ulcer disease such as bleeding, perforation, penetration or multiple recurrences in which case an H. pylori breath test may be used to document eradication of the infection in lieu of a follow-up endoscopy. CODING Covered CPT * Codes 78267 Urea Breath test, C-14, Isotopic; acquisition for analysis 78268 Urea Breath test, C-14, Isotopic; analysis 83009 Helicobacter pylori, blood test analysis for urease activity, non-radioactive isotope (C-13) 83013 H pylori; breath test analysis for unease activity, non-radioactive isotope; C13 83014 H pylori; drug administration 86677 H pylori; antibody 87338 H pylori, stool ; EIA or ELISA 87339 H pylori; EIA or ELISA HCPCS Level II Codes - No applicable codes. ICD-9-CM Procedure Codes - No applicable codes. DRAFT ICD-10-PCS Codes - No applicable codes. Clinical Coverage Guideline page 3

Covered ICD-9 Diagnosis Codes 041.86 Helicobacter Pylori [H. PYLORI] 530.81 Esophageal Reflux 531.00 Acute Gastric Ulcer with hemorrhage without obstruction 531.01 Acute Gastric Ulcer with hemorrhage with obstruction 531.10 Acute Gastric Ulcer with perforation without obstruction 531.11 Acute Gastric Ulcer with perforation with obstruction 531.20 Acute Gastric Ulcer with hemorrhage and perforation without obstruction 531.21 Acute Gastric Ulcer with hemorrhage and perforation with obstruction 531.30 Acute Gastric Ulcer without hemorrhage or perforation without obstruction 531.31 Acute Gastric Ulcer without hemorrhage or perforation with obstruction 531.40 Chronic or unspecified Gastric Ulcer with hemorrhage without obstruction 531.41 Chronic or unspecified Gastric Ulcer with hemorrhage with obstruction 531.50 Chronic or unspecified Gastric Ulcer with perforation without obstruction 531.51 Chronic or unspecified Gastric Ulcer with perforation with obstruction 531.60 Chronic or unspecified Gastric Ulcer with hemorrhage and perforation without obstruction 531.61 Chronic or unspecified Gastric Ulcer with hemorrhage and perforation with obstruction 531.70 Chronic Gastric Ulcer without hemorrhage or perforation without obstruction 5 31.71 Chronic Gastric Ulcer without hemorrhage or perforation with obstruction 531.90 Gastric Ulcer unspecified as acute or chronic without hemorrhage or perforation without obstruction 531.91 Gastric Ulcer unspecified as acute or chronic without hemorrhage or perforation with obstruction 532.00 Acute Duodenal Ulcer with hemorrhage without obstruction 532.01 Acute Duodenal Ulcer with hemorrhage with obstruction 532.10 Acute Duodenal Ulcer with perforation without obstruction 532.11 Acute Duodenal Ulcer with perforation with obstruction 532.20 Acute Duodenal Ulcer with hemorrhage and perforation without obstruction 532.21 Acute Duodenal Ulcer with hemorrhage and perforation with obstruction 532.30 Acute Duodenal Ulcer without hemorrhage or perforation without obstruction 532.31 Acute Duodenal Ulcer without hemorrhage or perforation with obstruction 532.40 Chronic or unspecified Duodenal Ulcer with hemorrhage without obstruction 532.41 Chronic or unspecified Duodenal Ulcer with hemorrhage with obstruction 532.50 Chronic or unspecified Duodenal Ulcer with perforation without obstruction 532.51 Chronic or unspecified Duodenal Ulcer with perforation with obstruction 532.60 Chronic or unspecified Duodenal Ulcer with hemorrhage and perforation without obstruction 532.61 Chronic or unspecified Duodenal Ulcer with hemorrhage and perforation with obstruction 532.70 Chronic Duodenal Ulcer without hemorrhage or perforation without obstruction 532.71 Chronic Duodenal Ulcer without hemorrhage or perforation with obstruction 532.90 Duodenal Ulcer unspecified as acute or chronic without hemorrhage or perforation without obstruction 532.91 Duodenal Ulcer unspecified as acute or chronic without hemorrhage or perforation with obstruction 533.00 Acute Peptic Ulcer of unspecified site with hemorrhage without obstruction 533.01 Acute Peptic Ulcer of unspecified site with hemorrhage with obstruction 533.10 Acute Peptic Ulcer of unspecified site with perforation without obstruction 533.11 Acute Peptic Ulcer of unspecified site with perforation with obstruction 533.20 Acute Peptic Ulcer of unspecified site with hemorrhage and perforation without obstruction 533.21 Acute Peptic Ulcer of unspecified site with hemorrhage and perforation with obstruction 533.30 Acute Peptic Ulcer of unspecified site without hemorrhage and perforation without obstruction 533.31 Acute Peptic Ulcer of unspecified site without hemorrhage and perforation with obstruction 533.40 Chronic or unspecified Peptic Ulcer of unspecified site with hemorrhage without obstruction 533.41 Chronic or unspecified Peptic Ulcer of unspecified site with hemorrhage with obstruction 533.50 Chronic or unspecified Peptic Ulcer of unspecified site with perforation without obstruction 533.51 Chronic or unspecified Peptic Ulcer of unspecified site with perforation with obstruction 533.60 Chronic or unspecified Peptic Ulcer of unspecified site with hemorrhage & perforation without obstruction Clinical Coverage Guideline page 4

533.61 Chronic or unspecified Peptic Ulcer of unspecified site with hemorrhage and perforation with obstruction 533.70 Chronic Peptic Ulcer of unspecified site without hemorrhage or perforation without obstruction 533.71 Chronic Peptic Ulcer of unspecified site without hemorrhage or perforation with obstruction 533.90 Peptic Ulcer of unspecified site unspecified as acute or chronic without hemorrhage or perforation without obstruction 533.91 Peptic Ulcer of unspecified site unspecified as acute or chronic without hemorrhage or perforation with obstruction 534.00 Acute Gastrojejunal Ulcer with hemorrhage without obstruction. 534.01 Acute Gastrojejunal Ulcer with hemorrhage with obstruction 534.10 Acute Gastrojejunal Ulcer with perforation without obstruction 534.11 Acute Gastrojejunal Ulcer with perforation with obstruction 534.20 Acute Gastrojejunal Ulcer with hemorrhage and perforation without obstruction 534.21 Acute Gastrojejunal Ulcer with hemorrhage and perforation with obstruction 534.30 Acute Gastrojejunal Ulcer without hemorrhage or perforation without obstruction 534.31 Acute Gastrojejunal Ulcer without hemorrhage or perforation with obstruction 534.40 Chronic or unspecified Gastrojejunal Ulcer with hemorrhage without obstruction 534.41 Chronic or unspecified Gastrojejunal Ulcer with hemorrhage with obstruction 534.50 Chronic or unspecified Gastrojejunal Ulcer with perforation without obstruction 534.51 Chronic or unspecified Gastrojejunal Ulcer with perforation with obstruction 534.60 Chronic or unspecified Gastrojejunal Ulcer with hemorrhage and perforation without obstruction 534.61 Chronic or unspecified Gastrojejunal Ulcer with hemorrhage and perforation with obstruction 534.70 Chronic Gastrojejunal Ulcer without hemorrhage or perforation without obstruction 534.71 Chronic Gastrojejunal Ulcer without hemorrhage or perforation with obstruction 534.90 Gastrojejunal Ulcer unspecified as acute or chronic without hemorrhage or perforation without obstruction 534.91 Gastrojejunal Ulcer unspecified as acute or chronic without hemorrhage or perforation with obstruction 535.00 Acute Gastritis without hemorrhage 535.01 Acute Gastritis with hemorrhage 535.10 Atrophic Gastritis without hemorrhage 535.11 Atrophic Gastritis with hemorrhage 535.20 Gastric Mucosal Hypertrophy without hemorrhage 535.21 Gastric Mucosal Hypertrophy with hemorrhage 535.30 Alcoholic Gastritis without hemorrhage 535.31 Alcoholic Gastritis with hemorrhage 535.40 Other specified Gastritis without hemorrhage 535.41 Other specified Gastritis with hemorrhage 535.50 Unspecified Gastritis and Gastroduodenitis without hemorrhage 535.51 Unspecified Gastritis and Gastroduodenitis with hemorrhage 535.60 Duodenitis without hemorrhage 535.61 Duodenitis with hemorrhage 536.2 Persistent vomiting 536.8 Dyspepsia and other specified disorders of function of stomach 537.89 Other specified disorders of stomach and duodenum 538 Gastrointestinal mucositis ulcerative 787.01 Nausea with vomiting 787.03 Vomiting Alone 787.1 Heartburn 787.3 Flatulence eructation and gas pain 789.01 Abdominal pain right upper quadrant 789.02 Abdominal pain left upper quadrant 789.06 Abdominal pain epigastric 793.4 Nonspecific Abnormal Findings on radiological and other examination of the gastrointestinal tract Clinical Coverage Guideline page 5

Non-Covered ICD-9-CM Diagnosis Code V74.9 Special Screen Examination for Bacterial and Spirochetal disease Covered Draft ICD-10-CM Diagnosis Codes B96.81 Helicobacter pylori (H.pylori) as the cause of disease classified elsewhere K21.9 Gastro-esophageal reflux disease without esophagitis K25.0 Acute gastric ulcer with hemorrhage K25.1 Acute gastric ulcer with perforation K25.2 Acute gastric ulcer with both hemorrhage and perforation K25.3 Acute gastric ulcer without hemorrhage or perforation K25.4 Chronic or unspecified gastric ulcer with hemorrhage K25.5 Chronic or unspecified gastric ulcer with perforation K25.6 Chronic or unspecified gastric ulcer with both hemorrhage and perforation K25.7 Chronic or unspecified gastric ulcer without hemorrhage or perforation K25.9 Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation K26.0 Acute duodenal ulcer with hemorrhage K26.1 Acute duodenal ulcer with perforation K26.2 Acute duodenal ulcer with both hemorrhage and perforation K26.3 Acute duodenal ulcer without hemorrhage or perforation K26.4 Chronic or unspecified duodenal ulcer with hemorrhage K26.5 Chronic or unspecified duodenal ulcer with perforation K26.6 Chronic or unspecified duodenal ulcer with both hemorrhage and perforation K26.7 Chronic duodenal ulcer without hemorrhage or perforation K26.9 Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation K27.0 Acute peptic ulcer, site unspecified, with hemorrhage K27.1 Acute peptic ulcer, site unspecified, with perforation K27.2 Acute peptic ulcer, site unspecified, with both hemorrhage and perforation K27.3 Acute peptic ulcer, site unspecified, without hemorrhage or perforation K27.4 Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage K27.5 Chronic or unspecified peptic ulcer, site unspecified, with perforation K27.6 Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage and perforation K27.7 Chronic or unspecified peptic ulcer, site unspecified, without hemorrhage or perforation K27.9 Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation K28.0 Acute Gastrojejunal ulcer with hemorrhage K28.1 Acute Gastrojejunal ulcer with perforation K28.2 Acute Gastrojejunal ulcer with hemorrhage and perforation K28.3 Acute Gastrojejunal ulcer without hemorrhage or perforation K28.4 Chronic or unspecified Gastrojejunal ulcer with hemorrhage K28.5 Chronic or unspecified Gastrojejunal ulcer with perforation K28.6 Chronic or unspecified Gastrojejunal ulcer with both hemorrhage and perforation K28.7 Chronic or unspecified Gastrojejunal ulcer without hemorrhage or perforation K28.9 Gastrojejunal ulcer, unspecified as acute or chronic, without hemorrhage or perforation K29.00 Acute gastritis without bleeding K29.01 Acute gastritis with bleeding K29.20 Alcoholic gastritis without bleeding K29.21 Alcoholic gastritis with bleeding K29.30 Chronic superficial gastritis without bleeding K29.31 Chronic superficial gastritis with bleeding K29.40 Chronic atrophic gastritis without bleeding K29.41 Chronic atrophic gastritis with bleeding K29.50 Unspecified chronic gastritis without bleeding K29.51 Unspecified chronic gastritis with bleeding Clinical Coverage Guideline page 6

K29.60 Other gastritis without bleeding K29.61 Other gastritis with bleeding K29.70 Gastritis, unspecified, without bleeding K29.71 Gastritis, unspecified, with bleeding K29.80 Duodenitis without bleeding K29.81 Duodenitis with bleeding K29.90 Gastroduodenitis, unspecified, without bleeding K39.91 Gastroduodenitis, unspecified, with bleeding R10.10 Upper abdominal pain, unspecified R10.11 Right upper quadrant pain R10.12 Left upper quadrant pain R11.10 Vomiting, unspecified R11.11 Vomiting without nausea R11.2 Nausea with vomiting, unspecified R12 Heartburn R14.0 Abdominal distension (gaseous) R14.1 Gas pain R14.2 Eructation R14.3 Flatulence R93.3 Abnormal findings on diagnostic imaging of other parts of digestive tract Non-Covered DRAFT ICD-10-CM Diagnosis Code Z11.2 Encounter for screening for other bacterial diseases *Current Procedural Terminology (CPT ) 2015 American Medical Association: Chicago, IL. REFERENCES 1. Chey W, Wong, BCY. American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection. American Journal of Gastroenterology. 2007; 102:1808 1825. 2. FDA approved first helicobacter pylori breath test for children. Hayes Directory Web site. Published February 27, 2012. http://www.hayesinc.com. Accessed August 19, 2015. 3. Quadruple therapy for treating helicobacter pylori. Hayes Directory Website. Published May 23, 2011. http://www.hayesinc.com. Accessed August 19, 2015. MEDICAL POLICY COMMITTEE HISTORY AND REVISIONS Date Action 7/11/2015, 8/7/2014, 8/1/2013 9/6/2012 Approved by MPC. No changes. Approved by MPC. Condensed background section. Added 2 new Hayes references re: 2012 FDA approval of testing in children and a study showing efficacy in shorter duration of treatment in eradicating H. pylori. No other substantive changes; coverage not altered. 12/1/2011 9/1/2011 New template design approved by MPC. Approved by MPC. Clinical Coverage Guideline page 7